Optimi Health and Numinus Wellness Submit All-Natural

Optimi Health and Numinus Wellness Submit All-Natural

News Highlights

VANCOUVER, British Columbia, May 11, 2021 (News) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.

Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary (“Impact”), have submitted a pre-clinical trial application to Health Canada for review and comment. Meanwhile, cultivation, research, formulation, and continuous validation studies to produce the investigational psilocybin extract for trial continue at the Health Canada-licensed Numinus lab in British Columbia, Canada.

Key information submitted in the information package provided to Health Canada includes the investigational product’s chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from Psilocybe mushrooms.

With Health Canada’s feedback and anticipated regulatory approvals, Numinus plans to use the candidate mushroom clone to develop a uniform all-natural psilocybin capsule for use in Optimi’s human clinical trials, initially for a dosing study and then expanding into trials for a variety of human health conditions.

Optimi will retain 100% ownership of the resulting all-natural psilocybin capsule and full intellectual property rights to its use.

Optimi Chairman of the Board JJ Wilson comments, “This is another important step for our commitment to the development of naturally sourced, evidence-based product formulations. As a cornerstone of our brand positioning, we believe that future consumer demand will be based on efficacy, cost, and source integrity. By using natural products, we seek to unlock the full value potential in this sector. With the work we are embarking on today with the teams at Numinus and Impact, we are aiming for what we hope will become blockbuster candidates able to significantly transform the mental health therapeutic landscape, while remaining true to historic principles and natural organic origins.”

“Numinus is pleased to partner with Optimi on this important work and provide the expertise, licensed facility and specialized equipment required to quickly develop, formulate and rigorously test products derived from natural Psilocybe sources and prepare them for Health Canada submissions and approvals,” said Sharan Sidhu, Science Officer and General Manager, Numinus Bioscience. “We look forward to continuing our work with Optimi to develop safe, standardized and reproducible products that provide meaningful and accurate clinical trial data.”

Numinus Bioscience recently received amendments to its federal license to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including – for the first time – Ketamine and Lysergic acid diethylamide (LSD). The amendment also supports Numinus Bioscience’s role in activities related to Mescaline, N, N-Dimethyltryptamine (DMT), N-Methyl 3,4, methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin.

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

ABOUT NUMINUS WELLNESSNuminus Wellness (TSX-V; NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

FOR FURTHER INFORMATION CONTACT:

Investor RelationsEmail: investors@optimihealth.ca Phone: +1 (778) 930-1321Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTSThis news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

  • Check the latest Health news updates and information.
  • Please share this news Optimi Health and Numinus Wellness Submit All-Natural with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
This $2,700 robot dog will carry a single bottle of water for you

SEC charges six with employers’ financial information

Source thehill.com The SEC also alleged that Bannon shared nonpublic information about his employer, Fortinet Inc., with Sood, who allegedly tipped off ...
Firmenich joins UN Global Compact CFO task force to drive corporate finance strategies with real-world ESG impacts

Firmenich joins UN Global Compact CFO task force to drive corporate finance strategies with real-world ESG impacts

By working across the investment value chain, including investors, banks, development finance institutions, credit ratings agencies and sustainability ...
Workforce Partnership Report Finds Employee-Owned  News Benefits

Workforce Partnership Report Finds Employee-Owned News Benefits

The San Diego Workforce Partnership offered several recommendations for interested businesses: Other benefits cited in the report: 72% of workers profiled ...
FaceTime, sharing, smarter alerts, and more are all included in iOS 15

Without an iPhone XS/XR or newer, you won’t be able to use these iOS 15 features

While Apple has often been accused of planned obsolescence, it doesn’t intentionally cripple or slow down older iPhones when newer iOS versions come out — at ...
UPDATE 1 - Financial and industrial stocks lift European stocks to a near-record peak

UPDATE 1 – Financial and industrial stocks lift European stocks to a near-record peak

The pan-European STOXX 600 was up 0.2% by 0745 GMT. If gains hold until the end of the day, the index will mark its longest gaining streak in three-and-a-half ...
The new UI, Start menu, and other features of Windows 11 have been leaked

The new UI, Start menu, and other features of Windows 11 have been leaked

The new Windows 11 user interface and Start menu look very similar to what was originally found in Windows 10X. Microsoft had been simplifying Windows for ...
On October 3rd, Super Monkey Ball: Banana Mania will be released on the PlayStation 4 and PlayStation 5

On October 3rd, Super Monkey Ball: Banana Mania will be released on the PlayStation 4 and PlayStation 5

The game will cost $39.99 and, if you pick up the physical Anniversary Edition, you’ll get an art book, reversible cover, collectible sleeve, and 10 cosmetic ...
Valerie Nurr'araaluk Davidson Named President of Alaska's Largest Tribal Health Organization

Valerie Nurr’araaluk Davidson Named President of Alaska’s Largest Tribal Health Organization

When he named her a commissioner, Walker described Davidson as an expert on Medicaid in Alaska. She played a vital role in the governor’s decision to expand ...
Mayor Jones Outlines Proposal on How to Spend Federal Stimulus Money |  St. Louis News Headlines

Mayor Jones Outlines Proposal on How to Spend Federal Stimulus Money | St. Louis News Headlines

Proposed economic relief: Nearly $59 millionRental and utility assistance: About $15 millionPermanent camps for the homeless: $1.5 millionPublic safety: $11.5 ...
Motorola Moto G60 First Impressions: Camera Focused

The Motorola RAZR may need to take a year off to work things out

Amid reports that other companies like Honor are gearing up to release foldable smartphones this year, Motorola apparently won’t be among them. The report ...
Show next
Compsmag - Latest News from tech, business and health
Logo